Mitsubishi Chemical Group. Science. Value. Life.
Explore Our Treatments

Scientific Publications

The links on this page are not affiliated with Mitsubishi Tanabe Pharma America, Inc. (MTPA). Links to sites outside of MTPA are provided as a resource to the viewer. MTPA accepts no responsibility for the content of linked sites. Some links may direct to third-party websites that require a subscription to access publications.

The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis
Brooks BR, Pioro EP, Sakata T, et al. Muscle Nerve. 2023;1–7. https://doi.org/10.1002/mus.27946
View Publication
Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis
Brooks BR, Berry JD, Ciepielewska M, et al. eClinicalMedicine. 2022;52:101590.
doi:10.1016/j.eclinm.2022.101590
View Publication
Edaravone administered orally and via nasogastric tube in healthy adults: a comparative bioavailability phase 1 study
Shimizu H, Nishimura Y, Shiide Y. Clin Pharmacol Drug Dev. Published online Oct 12, 2022. doi:10.1002/cpdd.1175
View Publication
Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19)
Shefner J, Heiman-Patterson T, Pioro EP, et al. Muscle Nerve. 2020;61(2):218-221.
doi:10.1002/mus.26740
View Publication
Analysis of the US safety data for edaravone (Radicava®) from the third year after launch
Genge A, Brooks BR, Oskarsson B, et al. Drugs R D. 2022;22(3):205-211. doi:10.1007/s40268-022-00391-6
View Publication
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19)
[clinical trial NCT01492686]
Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. PloS One. 2022;17(6):e0258614.
doi:10.1371/journal.pone.0258614
View Publication
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19
Brooks BR, Pioro EP, Katz J, et al. Muscle Nerve. 2022;65(2):180-186.
doi:10.1002/mus.27467
View Publication
Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study
Berry JD, Bedlack R, Mathews D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(1-2):147-150. doi:10.1080/21678421.2020.1804939
View Publication
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool
Brooks BR, Pioro EP, Beaulieu D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):49-57. doi:10.1080/21678421.2021.1927102
View Publication
Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19
Al-Chalabi A, Chiò A, Merrill C, et al. J Neurol Neurosurg Psychiatry. 2021;92(2):165-171.
doi:10.1136/jnnp-2020-323271
View Publication
Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center
Hagan M, Ciepielewska M, Harrison A, et al. Poster presented at virtual 31st International Symposium on ALS/MND; December 9-11, 2020.
View Publication
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1
View Publication
Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis
Palumbo JM, Hubble J, Apple S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):421-431. doi:10.1080/21678421.2019.1599955
View Publication
A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
The Edaravone (MCI-186) ALS 16 Study Group. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Sup1):11-19. doi:10.1080/21678421.2017.1363780
View Publication
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Genge A, Pattee GL, Sobue G, et al. Muscle Nerve. 2023; 67(2): 124-129. doi:10.1002/mus.27768
View Publication
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
Shimizu H, Nishimura Y, Shiide Y, et al. Clin. Pharmacol. Drug Dev. 2021; 10: 1188-1197. doi: 10.1002/cpdd.952
View Publication
Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults
Shimizu H, Nishimura Y, Shiide Y, et al. Clin. Pharmacol. Drug Dev. 2021; 10: 1174-1187. doi: 10.1002/cpdd.925
View Publication
Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants
Hidetoshi H, Nishimura Y, Shiide Y, et al. Clin. Ther., Volume 44, Issue 12, 2022, Pages 1552-1565, ISSN 0149-2918. doi: 10.1016/j.clinthera.2022.10.001.
View Publication
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
Abe K, Itoyama Y, Sobue G, et al. 2014. Amyotroph Lateral Scler Frontotemporal Degener, 15(7-8):610-617. doi: 10.3109/21678421.2014.959024
View Publication
Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study
Shimizu H, Nishimura Y, Shiide Y, et al. Clin. Pharmacol. Drug Dev. 2023. 12: 77-84. Doi: 10.1002/cpdd.1175
View Publication
Load More
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America, Inc.
This link will take you to a website to which our Privacy Policy and Terms of Use does not apply. Mitsubishi Tanabe Pharma America, Inc. does not control the content of this third-party site.
Continue
Cancel
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America, Inc.
This link will take you to a website to which our Privacy Policy and Terms of Use does not apply. Mitsubishi Tanabe Pharma America, Inc. does not control the content of this third-party site.
Continue
Cancel